Influenza Vaccine in HIV Study
Completed
- Conditions
- Influenza, Human
- Interventions
- Biological: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)
- Registration Number
- NCT02632578
- Lead Sponsor
- University of Melbourne
- Brief Summary
The aims of this study are:
1. to investigate if HIV infection alters the antibody responses to influenza and
2. to assess the ability of licensed influenza vaccine to induce functional non-neutralising antibodies in HIV-infected and HIV-uninfected subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 57
Inclusion Criteria
- HIV-1 positive by licensed diagnostic test (for HIV-positive group only)
- Planning to receive the seasonal influenza vaccine outside the study
- Provision of written informed consent
Exclusion Criteria
- Previous allergy to influenza vaccination
- Pregnancy or planning to become pregnant
- Unwilling or unable to provide blood samples
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description HIV-positive 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine) - HIV-negative 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine) -
- Primary Outcome Measures
Name Time Method Anti-influenza antibody responses in plasma with Fc-mediated functions Four weeks after influenza vaccination
- Secondary Outcome Measures
Name Time Method